Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 269

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 269
---
 7,405 |   |
| Issuance of additional 2020 Notes                      |     |   |    450 |   |
| Changes in fair value                                  |     |   | (3,483 | ) |
| Balance as of December 31, 2024                        |     | $ |  4,372 |   |

| NOTE 7:- | WARRANT LIABILITY |

| a. | As of January 1, 2023, the Company has issued 167,365 warrants in connection                                                         
 with the issuance of its convertible notes which are exercisable into convertible preferred D-2 shares. The warrants are exercisable 
 at the earlier of: (i) March 1, 2025, (ii) immediately prior to the closing of an IPO, (iii) upon occurrence of a Deemed             
 Liquidation Event, or (iv) immediately prior to the occurrence of a Liquidation Event, as described in Company’s Article of          
 Association (the “AOA”).                                                                                                             |

A Deemed Liquidation Event, as defined
in the AOA, includes change of control event in which shareholders of the Company, immediately prior to the event, hold less than 50%
of the voting power in the Company (or the surviving entity) after the event, as well as an event in which the Company sells substantially
all of its assets. In the occurrence of a Deemed Liquidation Event, all of the Company’s assets legally available for distribution among
the shareholders of the Company would be distributed in accordance with the preference described above. A Liquidation Event,
as defined in the AOA, includes any dissolution, winding-up or liquidation of the Company, and any foreclosure by creditors of the Company
on substantially all assets of, or equity interests in the Company, all whether voluntarily or involuntarily.

The exercise price of each warrant
is $15.20.

The number of the warrants and exercise
price were adjusted retroactively to reflect the Split, see Note 1c.

<div align='center'>F-18</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | WARRANT LIABILITY (Cont.) |

The warrants represent a freestanding
instrument accounted for at fair value and re-measured at each reporting date. The Company estimates the fair value of the warrants using
PWERM. A summary of significant unobservable inputs (